一分钟看懂
这是一项关于乳腺癌的II 期 / III 期研究，登记的药物或干预包括RO7771950；Tucatinib；Trastuzumab；Capecitabine，当前状态为招募中。登记地点显示中国南京、上海、北京、蚌埠等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
RO7771950；Tucatinib；Trastuzumab；Capecitabine · II 期 / III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出5项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School · 南京
- Ruijin Hospital Shanghai Jiaotong University School of Medicine · 上海
- Beijing Cancer Hospital · 北京
- Cancer Hospital Chinese Academy of Medical Sciences. · 北京
- Peking University People's Hospital · 北京
- the First Affiliated Hospital of Bengbu Medical College · 蚌埠
- West China Hospital, Sichuan University · 成都
- Fujian Medical University Union Hospital · 福州
- Sun yat-sen University Cancer Center · 广州
- Sun Yat-sen Memorial Hospital · 广州
- The Second Affiliated Hospital of Zhejiang University College · HangzhouZhejiang
- Anhui Provincial Hospital · 合肥
- Jiangmen Central Hospital · 江门
- Shandong Cancer Hospital · 济南
- Yunnan Cancer Hospital · 昆明
- Nanchang People?s Hospital · 南昌
- Guangxi Cancer Hospital of Guangxi Medical University · 南宁
- Fudan University Shanghai Cancer Center · 上海
- Tumor Hospital of the affiliated medical college of Shantou University · 汕头
- Shantou Center Hospital · 汕头
- Tianjin Cancer Hospital · 天津
- Xinjiang Medical University Cancer Hospital · 乌鲁木齐
- Tongji Hospital Tongji Medical College Huazhong University of Science and Technology · 武汉
- Hubei Cancer Hospital · 武汉
- The Second Affiliated Hospital of Xi?an Jiaotong University, College of Medicine · 西安
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Pathologically documented locally advanced inoperable (LAI) or metastatic breast cancer (MBC) with confirmed HER2-positive status by central laboratory.
- * Measurable disease as per by RECIST v1.1 in stage 1. Non-measurable disease allowed in stage 2.
- * Previously treated (stable or progressive) or previously untreated CNS metastases, or leptomeningeal metastases.
- * At least one prior line of anti-HER2-based therapy for LAI or metastatic disease.
- * Prior anti-HER2 antibody-drug conjugate (ADC), such as trastuzumab-deruxtecan (T-DXd) or trastuzumab emtansine (T-DM1), in any treatment setting. Participants without prior ADC therapy may only be enrolled if approved standard-of-care (SOC) anti-HER2 ADC is not locally accessible at screening, or if there is a prospectively documented clinical contraindication.
- * Prior tyrosine kinase inhibitor (TKI) in the (neo)adjuvant setting provided completion is \> 12 months ahead of LAI occurrence. Prior treatment with TKIs for LAI/MBC is not permitted.
- * Has protocol-defined adequate organ and bone marrow function.
- * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07413939；登记信息更新于 2026-10-06；本站同步于 2026-10-08，中国中心当前名额未经人工确认。